Oral Peptide Shows Durable Efficacy in Ulcerative Colitis

(MedPage Today) -- An oral peptide that blocks the interleukin-23 receptor demonstrated durable long-term efficacy in patients with moderately to severely active ulcerative colitis, according to results from the phase IIb ANTHEM-UC trial.
During...